RT Journal Article
SR Electronic
T1 Coagulopathy in COVID-19
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
DO 10.3949/ccjm.87a.ccc024
A1 Simon R. Mucha
A1 Siddharth Dugar
A1 Keith McCrae
A1 Douglas E. Joseph
A1 John Bartholomew
A1 Gretchen Sacha
A1 Michael Militello
YR 2020
UL http://www.ccjm.org/content/early/2020/05/12/ccjm.87a.ccc024.abstract
AB COVID-19-associated coagulopathy is common in patients with COVID-19, causing high rates of thrombotic complications that increase the morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings and correlate with severity of illness and risk of thrombosis. Aggressive VTE prophylaxis is paramount for all patients with COVID-19. Patients with very high D-dimer levels (6 times the upper limit of normal, greater than 3,000 ng/mL) have the greatest risk of thrombosis and may benefit from active screening and more intensive VTE prophylaxis.